Activity Details

0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hours
Released: November 21, 2017
Expires: November 20, 2018
30 minutes to complete

Provided By

This activity is provided by  

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who manage breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize efficacy data for CDK 4/6 inhibitors in the setting of advanced HR-positive, HER2-negative breast cancer
  • Identify differences in adverse events among the available CDK 4/6 inhibitors
  • Analyze available data to determine appropriate individualized treatment selection for patients with advanced HR-positive, HER2-negative breast cancer

Activity Description

The goal for this activity is to provide an expert perspective on frequently asked questions pertaining to the treatment of advanced HR-positive, HER2-negative breast cancer to help clinicians gain an enhanced understanding of this disease to offer the best possible treatment choices to their patients.

Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative represent the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Endocrine therapy is currently the cornerstone of treatment for advanced HR-positive breast cancer. However, not all patients respond to first-line endocrine therapy, and those that do respond eventually experience disease relapse. Resistance to endocrine therapy is common, and complete disease resistance to additional endocrine therapy eventually develops in patients with HR-positive metastatic breast cancer (MBC). The 5-year and 10-year survival rates for MBC are 26% and 5% to 10%, respectively. Significant therapeutic advances in this area include the development of agents that target critical pathways involved in the development of resistance to endocrine therapy. These include mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors.

This activity will focus on endocrine therapy, CDK 4/6 inhibitors, and treatment selection/sequencing.


Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Hematology-Oncology
Associate Director, Translational Research
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, Pennsylvania


Aju Mathew, MD, MPhil, FACP
Assistant Professor of Medicine
University of Kentucky
Lexington, Kentucky

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The author, Adam M. Brufsky, MD, PhD reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Received consulting fees from Lilly USA, Novartis  Pharmaceuticals Corp, Pfizer, Inc.

The co-author Aju Mathew, MD, MPhil, FACP has no real or apparent financial relationships to report.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko; Laura Healy; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD, reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars.

Continuing Education Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 0.5 contact hour of continuing pharmacy education credit. UAN 0592-0000-17-046-H01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.